Regulatory 2024-10-04 | Notice of Extraordinary General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-10-04 | Ascelia Pharma Announces Proposal for Election of Marianne Kock as New Member of the Board of Directors PDF Report Presentation Webcast
2024-10-01 | Ascelia Pharma Announces Acceptance of Orviglance SPARKLE Study Primary Results as Oral Presentation in Cutting-Edge Research at the 2024 RSNA Annual Meeting PDF Report Presentation Webcast
2024-09-30 | Ascelia Pharma Finalizes Rights Issue with Runway Extended to Late 2025 PDF Report Presentation Webcast
Regulatory 2024-09-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-09-13 | Ascelia Pharma Resolves on a Directed Issue of Convertibles of SEK 7.5 Million PDF Report Presentation Webcast
Regulatory 2024-09-05 | Ascelia Pharma Announces Final Outcome in Fully Subscribed SEK 105 Million Rights Issue PDF Report Presentation Webcast
Regulatory 2024-09-04 | Ascelia Pharma Announces Preliminary Outcome in Rights Issue PDF Report Presentation Webcast
Regulatory 2024-08-16 | Ascelia Pharma Announces Prospectus in Connection with Rights Issue PDF Report Presentation Webcast
Regulatory 2024-08-15 | Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-08-14 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 14 August 2024 PDF Report Presentation Webcast
Regulatory 2024-08-09 | Ascelia Pharma Announces Final Terms of Rights Issue PDF Report Presentation Webcast
Regulatory 2024-07-10 | Notice of Extraordinary General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-07-10 | Ascelia Pharma Carries Out a Rights Issue of Units of Approximately SEK 105 Million to Fully Finance the NDA Submission for Orviglance® PDF Report Presentation Webcast
Regulatory 2024-05-16 | Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
2024-05-07 | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients PDF Report Presentation Webcast
Regulatory 2024-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024 PDF Report Presentation Webcast
Regulatory 2024-05-02 | Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
